Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
19.06
-0.02 (-0.10%)
At close: Jul 15, 2026, 4:00 PM EDT
19.22
+0.16 (0.84%)
After-hours: Jul 15, 2026, 6:25 PM EDT

Viridian Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
0.9170.850.30.311.772.96
Revenue Growth (YoY)
201.99%23359.93%-3.82%-82.28%-40.20%182.19%
Gross Profit
0.9170.850.30.311.772.96
Selling, General & Admin
116.8995.3261.089535.1825.81
Research & Development
339.73338.93238.25159.77100.8956.89
Total Operating Expenses
456.62434.24299.34254.76136.0882.69
Operating Income
-385.7-363.4-299.04-254.45-134.3-79.73
Interest Income
27.7327.431.618.244.920.32
Interest Expense
-7.82-4.95-2.2-1.33-0.49-0
Other Non-Operating Income (Expense)
19.43-1.66-0.31-0.194.430.32
Total Non-Operating Income (Expense)
39.3420.7929.0916.728.860.63
Pretax Income
-346.36-342.6-269.95-237.73-125.44-79.1
Net Income
-360.59-342.6-269.95-237.73-129.87-79.41
Net Income to Common
-360.59-342.6-269.95-237.73-129.87-79.41
Shares Outstanding (Basic)
908568453212
Shares Outstanding (Diluted)
908568453212
Shares Change (YoY)
23.41%24.92%51.68%39.48%169.22%235.07%
EPS (Basic)
-3.32-3.32-3.07-3.91-2.71-6.66
EPS (Diluted)
-3.32-3.32-3.07-3.91-2.71-6.66
Free Cash Flow
-303.82-276.89-232.83-185.07-185.07-94.64
Free Cash Flow Per Share
-3.38-3.27-3.43-4.14-5.77-7.94
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-42291.40%-512.91%-99018.20%-81035.00%-7579.23%-2690.79%
Profit Margin
-39538.40%-483.56%-89387.10%-75711.50%-7329.23%-2680.16%
FCF Margin
-33314.00%-390.81%-77096.00%-58938.90%-10444.00%-3193.89%
EBITDA
-385.23-362.94-298.5-253.93-133.78-79.47
EBITDA Margin
-42240.60%-512.27%-98839.40%-80868.80%-7549.77%-2682.18%
EBIT
-385.7-363.4-299.04-254.45-134.3-79.73
EBIT Margin
-42291.40%-512.91%-99018.20%-81035.00%-7579.23%-2690.79%
SEC Filings: 10-K · 10-Q